TCM
ABBV icon

Teza Capital Management’s AbbVie ABBV Stock Holding History

Teza Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$343K Sell
1,577
-1,141
-42% -$253K 1.26% 26
2025
Q4 		$621K Buy
2,718
+1,251
+85% +$285K 2% 10
2025
Q3 		$340K Sell
1,467
-3,062
-68% -$624K 1.84% 22
2025
Q2 		$841K Buy
4,529
+177
+4% +$32.9K 0.63% 27
2025
Q1 		$912K Buy
4,352
+2,945
+209% +$573K 0.42% 67
2024
Q4 		$250K Sell
1,407
-3,629
-72% -$667K 0.04% 393
2024
Q3 		$995K Buy
5,036
+3,629
+258% +$677K 0.11% 259
2024
Q2 		$241K Buy
+1,407
New +$233K 0.03% 499
2024
Q1 		– Sell
-18,884
Closed -$2.93M – 548
2023
Q4 		$2.93M Buy
18,884
+14,032
+289% +$2.05M 0.49% 42
2023
Q3 		$723K Sell
4,852
-48,455
-91% -$7.11M 0.12% 244
2023
Q2 		$7.18M Buy
+53,307
New +$7.82M 1.17% 6
2023
Q1 		– Sell
-3,241
Closed -$524K – 488
2022
Q4 		$524K Buy
+3,241
New +$497K 0.1% 314
2022
Q1 		– Sell
-20,012
Closed -$2.71M – 398
2021
Q4 		$2.71M Buy
20,012
+16,154
+419% +$1.91M 0.73% 28
2021
Q3 		$416K Sell
3,858
-53,076
-93% -$6.06M 0.2% 156
2021
Q2 		$6.41M Buy
+56,934
New +$6.41M 1.04% 5
2021
Q1 		– Sell
-6,728
Closed -$721K – 457
2020
Q4 		$721K Sell
6,728
-19,123
-74% -$1.84M 0.41% 73
2020
Q3 		$2.26M Buy
+25,851
New +$2.43M 1.33% 4
2018
Q3 		– Sell
-10,872
Closed -$1.01M – 355
2018
Q2 		$1.01M Buy
10,872
+229
+2% +$22.4K 0.15% 236
2018
Q1 		$1.01M Buy
10,643
+2,479
+30% +$272K 0.24% 164
2017
Q4 		$790K Buy
+8,164
New +$769K 0.48% 88
2017
Q2 		– Sell
-14,201
Closed -$925K – 2
2017
Q1 		$925K Buy
+14,201
New +$893K 0.27% 117

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Teza Capital Management's ABBV Position: Q1 2026 in Review

Teza Capital Management reduced its AbbVie (ABBV) stake by 42% in Q1 2026, selling an estimated $253K and leaving 1,577 shares worth $343K. The position accounts for 1.26% of the portfolio, ranked #26.

Teza Capital Management first reported a position in ABBV in Q1 2017 and has held it in 21 quarters since. The position peaked at $7.18M in Q2 2023. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Teza Capital Management held 1,577 shares of AbbVie worth $343K as of Q1 2026.
  • Teza Capital Management sold 1,141 AbbVie shares in Q1 2026, an estimated $253K.
  • AbbVie made up 1.26% of Teza Capital Management's portfolio in Q1 2026, its #26 holding.
  • Teza Capital Management first reported a position in AbbVie in Q1 2017 and has held it in 21 quarters since.
  • Teza Capital Management's AbbVie position peaked at $7.18M in Q2 2023.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Teza Capital Management's 13F filing for Q1 2026, filed 15 May 2026.